Edesa Biotech president granted 64,609 RSUs

Brooks Michael J reported acquisition or exercise transactions in this Form 4 filing.

Accepted by SEC EDGAR 05/29/2026 - 05:01 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Brooks Michael J reported acquisition or exercise transactions in this Form 4 filing.

Edesa Biotech, Inc. President Michael J. Brooks reported an equity compensation award. He received 64,609 Common Shares in the form of restricted share units granted at a price of $0.00 per share under the company’s 2019 Equity Incentive Compensation Plan. These restricted share units vest monthly in equal portions over thirty-six months starting on the grant date of May 27, 2026. Following this award, Brooks directly holds a total of 291,479 Common Shares.

Insider Trade Summary

Grant/Award: 64,609 shares

Grant/Award 1 txn

Insider Brooks Michael J

Role President

Type	Security	Shares	Price	Value
Grant/Award	Common Shares	64,609	$0.00	$0.00

Holdings After Transaction: Common Shares — 291,479 shares (Direct)

Footnotes (1)

1. F1. Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest monthly in equal proportions over thirty-six (36) months, commencing on the grant date.

Key Figures

RSU grant size: 64,609 shares Grant price: $0.00 per share Total shares after grant: 291,479 shares +2 more

5 metrics

RSU grant size 64,609 shares Restricted share units granted on May 27, 2026

Grant price $0.00 per share Equity compensation, not an open-market purchase

Total shares after grant 291,479 shares Common Shares directly held by Michael J. Brooks after transaction

Vesting schedule 36 months, monthly RSUs vest monthly in equal portions over 36 months

Transaction type Grant, award, or other acquisition Form 4 code A, non-derivative Common Shares

Key Terms

restricted share units, 2019 Equity Incentive Compensation Plan, vest monthly in equal proportions, Form 4

4 terms

restricted share units financial

"Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan"

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

2019 Equity Incentive Compensation Plan financial

"restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan"

vest monthly in equal proportions financial

"which shall vest monthly in equal proportions over thirty-six (36) months"

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Edesa Biotech (EDSA) report for Michael J. Brooks?

Edesa Biotech reported that President Michael J. Brooks received 64,609 Common Shares as a restricted share unit grant. The award was made at $0.00 per share as equity compensation under the company’s 2019 Equity Incentive Compensation Plan.

How do the new restricted share units for Edesa Biotech’s president vest?

The 64,609 restricted share units granted to Edesa Biotech’s president vest monthly in equal proportions over thirty-six months. Vesting begins on the grant date of May 27, 2026, gradually delivering shares as long as service conditions are met.

What is Michael J. Brooks’ Edesa Biotech share ownership after this Form 4?

After the reported grant, Michael J. Brooks directly holds 291,479 Common Shares of Edesa Biotech. This total includes the newly awarded 64,609 restricted share units, which will vest over thirty-six months starting from the May 27, 2026 grant date.

Was cash involved in the Edesa Biotech (EDSA) equity grant to its president?

No cash changed hands in this transaction. The 64,609 Common Shares were granted at a price of $0.00 per share as a restricted share unit award, reflecting stock-based compensation rather than an open-market purchase or sale.

Under which plan were the Edesa Biotech restricted share units granted to Michael J. Brooks?

The restricted share units granted to Michael J. Brooks were issued under Edesa Biotech’s 2019 Equity Incentive Compensation Plan. This plan provides stock-based awards, such as restricted share units, as part of the company’s long-term executive compensation structure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brooks Michael J

(Last) (First) (Middle)

C/O EDESA BIOTECH INC.

100 SPY COURT

(Street)

MARKHAM L3R 5H6

(City) (State) (Zip)

ONTARIO, CANADA

(Country)

2. Issuer Name and Ticker or Trading Symbol
Edesa Biotech, Inc. [ EDSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	05/27/2026		A		64,609(1)	A	$0(1)	291,479	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest monthly in equal proportions over thirty-six (36) months, commencing on the grant date.

	/s/ Peter J. Weiler, Attorney-in-Fact for Michael J. Brooks	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)